Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

被引：492

作者：

Barker, AJ ^{[1
]}

Gibson, KH ^{[1
]}

Grundy, W ^{[1
]}

Godfrey, AA ^{[1
]}

Barlow, JJ ^{[1
]}

Healy, MP ^{[1
]}

Woodburn, JR ^{[1
]}

Ashton, SE ^{[1
]}

Curry, BJ ^{[1
]}

Scarlett, L ^{[1
]}

Henthorn, L ^{[1
]}

Richards, L ^{[1
]}

机构：

[1] AstraZeneca, Canc & Infect Res, Macclesfield SK10 4TG, Cheshire, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2001年 / 11卷 / 14期

关键词：

D O I：

10.1016/S0960-894X(01)00344-4

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：1911 / 1914

页数：4

共 50 条

[21] A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
Daneshmand, M
Parolin, DAE
Hirte, HW
Major, P
Goss, G
Stewart, D
Batist, G
Miller, WH
Matthews, S
Seymour, L
Lorimer, IAJ
CLINICAL CANCER RESEARCH, 2003, 9 (07) : 2457 - 2464
[22] ZD1839 (℈Iressa℉), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model
Williams K.J.
Telfer B.A.
Stratford I.J.
Wedge S.R.
British Journal of Cancer, 2002, 86 (7) : 1157 - 1161
[23] ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model
Williams, KJ
Telfer, BA
Stratford, IJ
Wedge, SR
BRITISH JOURNAL OF CANCER, 2002, 86 (07) : 1157 - 1161
[24] Clinically meaningful response to the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
Gelibter, A
Ceribelli, A
Milella, M
Mottolese, M
Vocaturo, A
Cognetti, F
BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S28
[25] A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa")
Yano, S
Kanematsu, T
Miki, T
Aono, Y
Azuma, M
Yamamoto, A
Uehara, H
Sone, S
CANCER SCIENCE, 2003, 94 (05) : 453 - 458
[26] ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows activity using a hepatocellular carcinoma model
Matsuo, M
Sakurai, H
Saiki, I
MOLECULAR CANCER THERAPEUTICS, 2003, 2 (06) : 557 - 561
[27] Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors
Nakagawa, K
Tamura, T
Negoro, S
Kudoh, S
Yamamoto, N
Yamamoto, N
Takeda, K
Swaisland, H
Nakatani, I
Hirose, M
Dong, RP
Fukuoka, M
ANNALS OF ONCOLOGY, 2003, 14 (06) : 922 - 930
[28] Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells
Sgambato, A
Camerini, A
Faraglia, B
Ardito, R
Bianchino, G
Spada, D
Boninsegna, A
Valentini, V
Cittadini, A
JOURNAL OF CELLULAR PHYSIOLOGY, 2004, 201 (01) : 97 - 105
[29] Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa)
Heimberger, AB
Learn, CA
Archer, GE
McLendon, RE
Chewning, TA
Tuck, TL
Pracyk, JB
Friedman, AH
Friedman, HS
Bigner, DD
Sampson, JH
CLINICAL CANCER RESEARCH, 2002, 8 (11) : 3496 - 3502
[30] Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa™), an EGFR-selective tyrosine kinase inhibitor.
Ciardiello, F
Caputo, R
Pomatico, G
Damiano, V
Bianco, R
Fontanini, G
Cuccato, S
De Placido, S
Bianco, AR
Tortora, G
CLINICAL CANCER RESEARCH, 2000, 6 : 4542S - 4542S

← 1 2 3 4 5 →